Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
International Journal of Colorectal Disease
Erschienen in: International Journal of Colorectal Disease 9/2018

05.07.2018 | Review

‘Watch and wait’ in rectal cancer: summary of the current evidence

verfasst von: Jason On, Emad H Aly

Erschienen in: International Journal of Colorectal Disease | Ausgabe 9/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

The management of rectal cancer has evolved considerably over the last few decades with increasing use of neoadjuvant chemoradiotherapy (nCRT). Complete clinical response (cCR) and even complete pathological response (pCR) have been noted in a proportion of patients who had surgery after nCRT. This raises the concern that we may have been ‘over-treating’ some of these patients and lead to an increasing interest in ‘watch and wait’ (W&W) approach for patients who had cCR to avoid the morbidity associated with rectal surgery.

Methods

A review of the literature in English pertaining to rectal cancer in the context of W&W, organ preservation and active surveillance.

Results

Evidence available to support W&W approach comes from non-randomised controlled trials (RCTs) with no current consensus on patients’ selection criteria, lack of viable predictors of both cCR and pCR and lack of universal definitions of cCR and pCR. Also, there is no agreed protocol for disease surveillance.

Conclusion

Even though there has been increasing reports on the outcomes of W&W in rectal cancer, the current evidence cannot support its routine use in clinical practice. This approach should be used in clinical trials settings or after thorough counselling with the patient on the outcomes of various treatment options.
Literatur
1.
Aly EH (2014) Time for a renewed strategy in the management of rectal cancer: critical reflection on the surgical management of rectal cancer over 100 years. Dis Colon Rectum 57(3):399–402CrossRefPubMed
2.
Nelson H, Petrelli N, Carlin A, Couture J, Fleshman J, Guillem J, Miedema B, Ota D, Sargent D, National Cancer Institute Expert Panel (2001) Guidelines 2000 for Colon and Rectal Cancer Surgery. JNCI J Natl Cancer Inst 93(8):583–596CrossRefPubMed
3.
Lai C-L, Lai M-J, Wu C-C, Jao S-W, Hsiao C-W (2016) Rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy, surgery, or “watch and wait”. Int J Color Dis 31(2):413–419CrossRef
4.
Grumann MM, Noack EM, Hoffmann IA, Schlag PM (2001) Comparison of quality of life in patients undergoing abdominoperineal extirpation or anterior resection for rectal cancer. Ann Surg 233(2):149–156CrossRefPubMedPubMedCentral
5.
Shearer R, Gale M, Aly OE, Aly EH (2013) Have early postoperative complications from laparoscopic rectal cancer surgery improved over the past 20 years? Colorectal Dis Off J Assoc Coloproctol G B Irel 15(10):1211–1226
6.
Scarpinata R, Aly EH (2013) Does robotic rectal cancer surgery offer improved early postoperative outcomes? Dis Colon Rectum 56(2):253–262CrossRefPubMed
7.
Smith FM, Waldron D, Winter DC (2010) Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 97(12):1752–1764CrossRefPubMed
8.
Kalyan A, Rozelle S, Benson A (2016) Neoadjuvant treatment of rectal cancer: where are we now? Gastroenterol Rep 4(3):206–209CrossRef
9.
Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740CrossRefPubMed
10.
Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373(9666):811–820CrossRefPubMedPubMedCentral
11.
Li Y, Wang J, Ma X, Tan L, Yan Y, Xue C, Hui B, Liu R, Ma H, Ren J (2016) A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci 12(8):1022–1031CrossRefPubMedPubMedCentral
12.
Habr-Gama A, Sao Juliao GP, Gama-Rodrigues J, Vailati BB, Ortega C, Fernandez LM et al (2017) Baseline T classification predicts early tumor regrowth after nonoperative management in distal rectal cancer after extended neoadjuvant chemoradiation and initial complete clinical response. Dis Colon Rectum 60(6):586–594CrossRefPubMed
13.
Sanghera P, Wong DWY, McConkey CC, Geh JI, Hartley A (2008) Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response. Clin Oncol 20(2):176–183CrossRef
14.
Fleming FJ, Monson JRT (2014) The contemporary (over)treatment of rectal cancer: the goldilocks effect. Dis Colon Rectum 57(3):403–406CrossRefPubMed
15.
Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U, Silva e Sousa AH et al (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240(4):711–717 discussion 717–718PubMedPubMedCentral
16.
Maas M, Beets-Tan RGH, Lambregts DMJ, Lammering G, Nelemans PJ, Engelen SME, van Dam RM, Jansen RLH, Sosef M, Leijtens JWA, Hulsewé KWE, Buijsen J, Beets GL (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 29(35):4633–4640CrossRef
17.
Dalton RSJ, Velineni R, Osborne ME, Thomas R, Harries S, Gee AS et al (2012) A single-centre experience of chemoradiotherapy for rectal cancer: is there potential for nonoperative management? Colorectal Dis Off J Assoc Coloproctol G B Irel 14(5):567–571
18.
Creavin B, Ryan E, Martin ST, Hanly A, O’Connell PR, Sheahan K et al (2017) Organ preservation with local excision or active surveillance following chemoradiotherapy for rectal cancer. Br J Cancer 116(2):169–174CrossRefPubMed
19.
Pomerri F, Crimì F, Veronese N, Perin A, Lacognata C, Bergamo F, Boso C, Maretto I (2017) Prediction of N0 irradiated rectal cancer comparing MRI before and after preoperative chemoradiotherapy. Dis Colon Rectum 60(11):1184–1191CrossRefPubMed
20.
21.
Swellengrebel HAM, Bosch SL, Cats A, Vincent AD, Dewit LGH, Verwaal VJ, Nagtegaal ID, Marijnen CAM (2014) Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome. Radiother Oncol J Eur Soc Ther Radiol Oncol 112(1):44–51CrossRef
22.
Hughes R, Harrison M, Glynne-Jones R (2010) Could a wait and see policy be justified in T3/4 rectal cancers after chemo-radiotherapy? Acta Oncol Stockh Swed 49(3):378–381CrossRef
23.
Smith JD, Ruby JA, Goodman KA, Saltz LB, Guillem JG, Weiser MR, Temple LK, Nash GM, Paty PB (2012) Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg 256(6):965–972CrossRefPubMed
24.
Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, Melis M (2012) Complete pathologic response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 19(9):2822–2832CrossRefPubMed
25.
Harrison JD, Solomon MJ, Young JM, Meagher A, Butow P, Salkeld G et al (2008) Patient and physician preferences for surgical and adjuvant treatment options for rectal cancer. Arch Surg Chic Ill 1960 143(4):389–394
26.
Habr-Gama A, Sao Juliao GP, Vailati BB, Sabbaga J, Aguilar PB, Fernandez LM et al (2017) Organ preservation in cT2N0 rectal cancer after neoadjuvant chemoradiation therapy: the impact of radiation therapy dose-escalation and consolidation chemotherapy. Ann Surg [Internet]. ((Habr-Gama) *Angelita & Joaquim Gama Institute, Sao Paulo, Brazil +University of Sao Paulo School of Medicine, Sao Paulo, Brazil ++Clinical Oncology Division, Instituto do Cancer do Estado de Sao Paulo (ICESP), Sao Paulo, Brazil Radiation Oncology Division, Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil PLudwig Institute for Cancer Research, Sao Paulo Branch, Sao Paulo, Brazil.). Available from: http://​journals.​lww.​com/​annalsofsurgery/​pages/​default.​aspx
27.
Bitterman DS, Resende Salgado L, Moore HG, Sanfilippo NJ, Gu P, Hatzaras I et al (2015) Predictors of complete response and disease recurrence following chemoradiation for rectal cancer. Front Oncol 5:286CrossRefPubMedPubMedCentral
28.
Song JH, Park Y-H, Seo SH, Lee A, Kim KH, An MS, Bae KB, Hong KH, Hwang JW, Kim JH, Jung HS, Ahn KJ (2017) Difference in tumor area as a predictor of a pathological complete response for patients with locally advanced rectal cancer. Ann Coloproctol 33(6):219–226CrossRefPubMedPubMedCentral
29.
Fontana E, Pucci F, Camisa R, Bui S, Galdy S, Leonardi F, Negri FV, Anselmi E, Losardo PL, Roncoroni L, Dell'abate P, Crafa P, Cascinu S, Ardizzoni A (2013) Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. Anticancer Res 33(2):725–730PubMed
30.
Yang Y-J, Cao L, Li Z-W, Zhao L, Wu H-F, Yue D, Yang JL, Zhou ZR, Liu SX (2016) Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: an updated systematic review and meta-analysis. Oncotarget 7(29):45513–45524CrossRefPubMedPubMedCentral
31.
Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A et al (2017) Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv22–iv40CrossRefPubMed
32.
Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 53(12):1692–1698CrossRefPubMed
33.
Smith FM, Chang KH, Sheahan K, Hyland J, O’Connell PR, Winter DC (2012) The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 99(7):993–1001CrossRefPubMed
34.
35.
van der Paardt MP, Zagers MB, Beets-Tan RGH, Stoker J, Bipat S (2013) Patients who undergo preoperative chemoradiotherapy for locally advanced rectal cancer restaged by using diagnostic MR imaging: a systematic review and meta-analysis. Radiology 269(1):101–112CrossRefPubMed
36.
Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K, Brown G (2011) Magnetic resonance imaging–detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29(28):3753–3760CrossRefPubMed
37.
Bhoday J, Smith F, Siddiqui MR, Balyasnikova S, Swift RI, Perez R, Habr-Gama A, Brown G (2016) Magnetic resonance tumor regression grade and residual mucosal abnormality as predictors for pathological complete response in rectal cancer postneoadjuvant chemoradiotherapy. Dis Colon Rectum 59(10):925–933CrossRefPubMed
38.
Patel UB, Blomqvist LK, Taylor F, George C, Guthrie A, Bees N, Brown G (2012) MRI after treatment of locally advanced rectal cancer: how to report tumor response—the MERCURY experience. Am J Roentgenol 199(4):W486–W495CrossRef
39.
Dos Anjos DA, Perez RO, Habr-Gama A, São Julião GP, Vailati BB, Fernandez LM et al (2016) Semiquantitative volumetry by sequential PET/CT may improve prediction of complete response to neoadjuvant chemoradiation in patients with distal rectal cancer. Dis Colon Rectum 59(9):805–812CrossRefPubMed
40.
Joye I, Debucquoy A, Deroose CM, Vandecaveye V, Cutsem EV, Wolthuis A, D'Hoore A, Sagaert X, Zhou M, Gevaert O, Haustermans K (2017) Quantitative imaging outperforms molecular markers when predicting response to chemoradiotherapy for rectal cancer. Radiother Oncol J Eur Soc Ther Radiol Oncol 124(1):104–109CrossRef
41.
Verseveld M, de Graaf EJR, Verhoef C, van Meerten E, Punt CJA, de Hingh IHJT, Nagtegaal ID, Nuyttens JJME, Marijnen CAM, de Wilt JHW, the CARTS Study Group (2015) Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 102(7):853–860CrossRefPubMed
42.
Maas M, Lambregts DMJ, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JWA, Sosef M, Hulsewé KWE, Hoff C, Breukink SO, Stassen L, Beets-Tan RGH, Beets GL (2015) Assessment of clinical complete response after chemoradiation for rectal cancer with digital rectal examination, endoscopy, and MRI: selection for organ-saving treatment. Ann Surg Oncol 22(12):3873–3880CrossRefPubMedPubMedCentral
43.
Smith RK, Fry RD, Mahmoud NN, Paulson EC (2015) Surveillance after neoadjuvant therapy in advanced rectal cancer with complete clinical response can have comparable outcomes to total mesorectal excision. Int J Color Dis 30(6):769–774CrossRef
44.
Araujo ROC, Valadão M, Borges D, Linhares E, de Jesus JP, Ferreira CG, Victorino AP, Vieira FM, Albagli R (2015) Nonoperative management of rectal cancer after chemoradiation opposed to resection after complete clinical response. A comparative study. Eur J Surg Oncol EJSO 41(11):1456–1463CrossRefPubMed
45.
Li J, Liu H, Yin J, Liu S, Hu J, Du F et al (2015) Wait-and-see or radical surgery for rectal cancer patients with a clinical complete response after neoadjuvant chemoradiotherapy: a cohort study. Oncotarget 6(39):42354–42361PubMedPubMedCentral
46.
Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean J-P, Partensky C, Souquet JC, Adeleine P, Gerard JP (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 17(8):2396–2396CrossRefPubMed
47.
Petrelli F, Sgroi G, Sarti E, Barni S (2016) Increasing the interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer: a meta-analysis of published studies. Ann Surg 263(3):458–464CrossRefPubMed
48.
Hupkens BJP, Maas M, Martens MH, van der Sande ME, Lambregts DMJ, Breukink SO, Melenhorst J, Houwers JB, Hoff C, Sosef MN, Leijtens JWA, Berbee M, Beets-Tan RGH, Beets GL (2018) Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response? Ann Surg Oncol 25(1):197–203CrossRefPubMed
49.
Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech JJ, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E (2016) Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal Cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol 34(31):3773–3780CrossRefPubMed
50.
Dossa F, Chesney TR, Acuna SA, Baxter NN (2017) A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2(7):501–513CrossRefPubMed
51.
Appelt AL, Pløen J, Harling H, Jensen FS, Jensen LH, Jørgensen JCR, Lindebjerg J, Rafaelsen SR, Jakobsen A (2015) High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. Lancet Oncol 16(8):919–927CrossRefPubMed
52.
Vaccaro CA, Yazyi FJ, Ojra Quintana G, Santino JP, Sardi ME, Beder D, Tognelli J, Bonadeo F, Lastiri JM, Rossi GL (2016) Locally advanced rectal cancer: preliminary results of rectal preservation after neoadjuvant chemoradiotherapy. Cirugia Espanola 94(5):274–279CrossRefPubMed
53.
Renehan AG, Malcomson L, Emsley R, Gollins S, Maw A, Myint AS, Rooney PS, Susnerwala S, Blower A, Saunders MP, Wilson MS, Scott N, O'Dwyer ST (2016) Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis. Lancet Oncol 17(2):174–183CrossRefPubMed
54.
Sammour T, Price BA, Krause KJ, Chang GJ (2017) Nonoperative management or “watch and wait” for rectal cancer with complete clinical response after neoadjuvant chemoradiotherapy: a critical appraisal. Ann Surg Oncol 24:1904–1915CrossRefPubMedPubMedCentral
55.
Bujko K (2017) Rectal cancer patients can be treated conservatively. Nowotw J Oncol 67(2):146–151CrossRef
56.
57.
Habr-Gama A, Lynn PB, Jorge JMN, São Julião GP, Proscurshim I, Gama-Rodrigues J, Fernandez LM, Perez RO (2016) Impact of organ-preserving strategies on anorectal function in patients with distal rectal cancer following neoadjuvant chemoradiation. Dis Colon Rectum 59(4):264–269CrossRefPubMed
58.
Hupkens BJP, Martens MH, Stoot JH, Berbee M, Melenhorst J, Beets-Tan RG, Beets GL, Breukink SO (2017) Quality of life in rectal cancer patients after chemoradiation: watch-and-wait policy versus standard resection—a matched-controlled study. Dis Colon Rectum 60(10):1032–1040CrossRefPubMed
59.
60.
Rombouts AJM, Al-Najami I, Abbott NL, Appelt A, Baatrup G, Bach S et al (2017) Can we save the rectum by watchful waiting or TransAnal microsurgery following (chemo) Radiotherapy versus Total mesorectal excision for early REctal Cancer (STAR-TREC study)?: protocol for a multicentre, randomised feasibility study. BMJ Open 7(12):e019474PubMedPubMedCentral
61.
Battersby NJ, Dattani M, Rao S, Cunningham D, Tait D, Adams R, Moran BJ, Khakoo S, Tekkis P, Rasheed S, Mirnezami A, Quirke P, West NP, Nagtegaal I, Chong I, Sadanandam A, Valeri N, Thomas K, Frost M, Brown G (2017) A rectal cancer feasibility study with an embedded phase III trial design assessing magnetic resonance tumour regression grade (mrTRG) as a novel biomarker to stratify management by good and poor response to chemoradiotherapy (TRIGGER): study protocol for a randomised controlled trial. Trials [Internet]. [cited 2018 Apr 10];18(1). Available from: http://​trialsjournal.​biomedcentral.​com/​articles/​10.​1186/​s13063-017-2085-2
62.
Metadaten
Titel
‘Watch and wait’ in rectal cancer: summary of the current evidence
verfasst von
Jason On
Emad H Aly
Publikationsdatum
05.07.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
International Journal of Colorectal Disease / Ausgabe 9/2018
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-018-3116-5

Weitere Artikel der Ausgabe 9/2018

International Journal of Colorectal Disease 9/2018 Zur Ausgabe

Original Article

The effect of gender on early colonic anastomotic wound healing

Correction

Correction to: Interstitial cells of Cajal increased in patients with rectal prolapse

Original Article

Various clinicopathological features of patients with metachronous colorectal cancer in relation to different diagnostic intervals

Original Article

Ulcerative colitis and the aging-related development of colonic diverticula

Original Article

Acute kidney injury following implementation of an enhanced recovery after surgery (ERAS) protocol in colorectal surgery

Original Article

Short-term outcomes and benefits of ERAS program in elderly patients undergoing colorectal surgery: a case-matched study compared to conventional care

Neu im Fachgebiet Chirurgie

17.04.2024 | Postoperative nausea and vomiting | Nachrichten

Hochrisiko-Eingriffe für postoperative Übelkeit

16.04.2024 | Infektiologie | Nachrichten

Kein Abstrich bei chronischen Wunden ohne Entzündungszeichen!

10.04.2024 | Postoperative Schmerztherapie | Nachrichten

Chronische Schmerzen nach Op. oft mit neuropathischer Komponente

10.04.2024 | Narbenhernie | Nachrichten

Deutlich weniger Narbenhernien mit der Small-Bites-Technik
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom CME-Kurs
CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur CME-Kurs
CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis CME-Kurs
CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.